U.S. Supreme Court’s Review of Hikma v. Amarin: A Pivotal Moment for Patent Law and Generic Drug Market
The U.S. Supreme Court’s decision to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. heralds significant consequences for patent law and beyond. At its core, the case delves into the intersection of patent law, FDA regulations, and the competitive landscape of generic pharmaceuticals. Originating from a 2024 ruling by the U.S. Court of Appeals…